Compare Merck & Co., Inc. (MRK) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Newegg Commerce Inc — how do they compare? Merck & Co., Inc. trades at $146.21 (market cap $351.28B), while Newegg Commerce Inc trades at $11.72 (market cap $243.30M). The key difference: Merck & Co., Inc. is far larger — about 1443.8× Newegg Commerce Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Newegg Commerce Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Newegg Commerce Inc for 14 Days on average.
| MRK | NEGG | |
|---|---|---|
Market Cap | $351.28B | $243.30M |
Volume | 7,969,665 | 41,252 |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $92.74 |
52-Week Low | $82.49 | $11.49 |
Typical Hold Time | 98 Days | 14 Days |
Enterprise Value | $398.04B | $213.53M |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
NEGG trades at $11.69, down 2.66% today, with a bearish technical signal from moving averages but oversold RSI readings. The company shows improving fundamentals with revenue stabilizing around $1.4B and net losses narrowing significantly from -$59M in 2023 to -$4.88M in 2025. Recent earnings beats and strategic partnerships with Western Digital and HPE highlight operational progress, though negative operating cash flow and insider selling present concerns.
The outlook remains mixed with improving profitability trends but significant execution risks. Valuation appears reasonable with P/S of 0.18x, but analyst consensus target of $7.75 suggests 34% downside. Key risks include competitive e-commerce pressures and the need to sustain recent operational improvements amid challenging market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
